Aicar vs MOTS-c: Comparing the Indexed Record
The practical distance between Aicar and MOTS-c shows up first in how much published methodology exists for each.
Compound profiles
Aicar in the indexed record
The literature on Aicar is a substantial body of work: 2,421 PubMed-indexed records, alongside 6 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Cell Mol Life Sci, Cells, Int J Mol Sci, spanning 2021–2025.
- AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review — Cells, 2021. PMID: 34064363
- Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy — Int J Mol Sci, 2024. PMID: 39795939
- AICAR confers prophylactic cardioprotection in doxorubicin-induced heart failure in rats — J Mol Cell Cardiol, 2024. PMID: 38643934
- Liposome-encapsulated AICAR hydrogel regulates macrophage metabolic reprogramming via SIK1 activation to alleviate osteoarthritis — J Nanobiotechnology, 2025. PMID: 40616103
MOTS-c in the indexed record
The literature on MOTS-c is a moderate body of work: 255 PubMed-indexed records, alongside 9 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Adv Sci (Weinh), Cardiovasc Drugs Ther, Front Endocrinol (Lausanne), spanning 2022–2025.
- Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination — Adv Sci (Weinh), 2024. PMID: 39321430
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes — Redox Biol, 2025. PMID: 40403491
- MOTS-c: Magical Molecule for Diabetic Cardiomyopathy? — Cardiovasc Drugs Ther, 2025. PMID: 40172798
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne), 2023. PMID: 36761202
Side-by-side research profile
| Parameter | Aicar | MOTS-c |
|---|---|---|
| PubMed indexed records | 2,421 | 255 |
| Registered studies (ClinicalTrials.gov) | 6 | 9 |
| Literature depth | Extensive | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Aicar and MOTS-c sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Aicar describes conditions validated for Aicar: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to MOTS-c without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
How the literature differs
The indexed record is not symmetrical between these two compounds. Aicar carries 2,166 more indexed records than MOTS-c, which means published methodology, characterisation data and replication attempts are more readily located for Aicar. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (6 vs 9) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Selecting between them for a study design
Aicar and MOTS-c are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Aicar) generally offers more methodological precedent.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Frequently asked questions
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Which of Aicar or MOTS-c has more published research?
Aicar, with 2,421 indexed PubMed records against 255.
Are Aicar and MOTS-c the same compound?
No. They are structurally distinct research compounds with separate literature records — 2,421 indexed records for Aicar and 255 for MOTS-c.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Related references
- MOTS-c — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.